LABORATORY CORP OF AMERICA HOLDINGS
8-K, 2000-06-26
MEDICAL LABORATORIES
Previous: LABORATORY CORP OF AMERICA HOLDINGS, 8-K, EX-20, 2000-06-26
Next: LABORATORY CORP OF AMERICA HOLDINGS, 8-K, EX-20, 2000-06-26






      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
                        JUNE 20, 2000
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission         (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                    Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)


<PAGE>

ITEM 5. OTHER EVENTS

  On  June  20,  2000,  Laboratory Corporation  of  America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-
)  announced that it has entered into a definitive agreement
with  privately-held National Genetics Institute, Inc. (NGI)
to  acquire all of the stock of NGI.  Established  in  1991,
Los  Angeles-based  NGI is a leading  national  provider  of
hepatitis   C  (HCV)  testing  using  innovative   molecular
diagnostic  technology.  Its customers  include  physicians,
drug   companies  performing  clinical  trials,  and  plasma
product  companies.  Terms of the definitive agreement  were
not  disclosed.   The transaction, which is expected  to  be
completed  in  July, is subject to certain,  normal  closing
conditions.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      20  Press release of the Company dated
          June 20, 2000.


<PAGE>
                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                         (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: June 21, 2000

<PAGE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission